North Growth Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

North Growth Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-163,000	Closed	-$18.9M	–	51
2023 Q3	$18.9M	Sell	163,000 -3,000	-2%	-$322K	4.19%	4
2023 Q2	$17.1M	Buy	166,000 +10,000	+6%	+$1.06M	3.52%	4
2023 Q1	$17.1M	Sell	156,000 -3,000	-2%	-$332K	3.64%	4
2022 Q4	$18.1M	Hold	159,000	–	–	4.12%	3
2022 Q3	$9.86M	Hold	159,000	–	–	2.46%	15
2022 Q2	$12.7M	Buy	159,000 +38,000	+31%	+$3.6M	2.94%	11
2022 Q1	$12.7M	Buy	+121,000	New	+$11.8M	2.35%	16

Other funds holding HZNP

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Blue Trust Inc Alpharetta, Georgia $9.51B AUM 13.02% 1-Year Est. Return

VWA

Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return

FSWA

Financial Synergies Wealth Advisors Houston, Texas $1.22B AUM 22.8% 1-Year Est. Return

BCMLT

Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

North Growth Management's HZNP Position: Q4 2023 in Review

North Growth Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 163,000 shares — an estimated $18.9M sold.

North Growth Management first reported a position in HZNP in Q1 2022 and held it in 7 quarters. The position peaked at $18.9M in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

North Growth Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
North Growth Management sold 163,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $18.9M.
North Growth Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2022 and held it in 7 quarters.
North Growth Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $18.9M in Q3 2023.
6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on North Growth Management's 13F filing for Q4 2023, filed 7 Feb 2024.